Cadilas Biologics manufacturing facility clears USFDA inspection

Biologics is not a big part of Cadilas portfolio at the moment, however it is expecting to generate $200mn revenue from biologic products by 2021.

from India Infoline News Service https://ift.tt/2LmbUjy